ATE325874T1 - Cd154 varianten und deren verwendung - Google Patents
Cd154 varianten und deren verwendungInfo
- Publication number
- ATE325874T1 ATE325874T1 AT01946167T AT01946167T ATE325874T1 AT E325874 T1 ATE325874 T1 AT E325874T1 AT 01946167 T AT01946167 T AT 01946167T AT 01946167 T AT01946167 T AT 01946167T AT E325874 T1 ATE325874 T1 AT E325874T1
- Authority
- AT
- Austria
- Prior art keywords
- cell
- methods
- wildtype
- mutant
- expression
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000009877 rendering Methods 0.000 abstract 1
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21065700P | 2000-06-09 | 2000-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE325874T1 true ATE325874T1 (de) | 2006-06-15 |
Family
ID=22783741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01946167T ATE325874T1 (de) | 2000-06-09 | 2001-06-08 | Cd154 varianten und deren verwendung |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1294874B1 (de) |
| JP (1) | JP2004503237A (de) |
| AT (1) | ATE325874T1 (de) |
| AU (1) | AU2001268250A1 (de) |
| CA (1) | CA2411472A1 (de) |
| CY (1) | CY1105153T1 (de) |
| DE (1) | DE60119517T2 (de) |
| DK (1) | DK1294874T3 (de) |
| ES (1) | ES2264697T3 (de) |
| NZ (1) | NZ523351A (de) |
| PT (1) | PT1294874E (de) |
| WO (1) | WO2001096397A2 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1423144A4 (de) * | 2001-08-10 | 2006-08-02 | Univ South Florida | Verfahren und verbindungen zur unterbrechung der cd40r/cd40l signalübertragung bei der behandlung der alzheimer-krankheit |
| WO2005100558A1 (ja) * | 2004-04-16 | 2005-10-27 | Hokkaido | Ｃｄ４０リガンドの変異体およびその使用 |
| CN102131931A (zh) * | 2008-05-22 | 2011-07-20 | 西马生物医学计划公司 | 递送腺病毒载体的衔接分子 |
| CA3045944A1 (en) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3054632A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| CN113348011B (zh) | 2018-11-19 | 2023-04-18 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
-
2001
- 2001-06-08 AU AU2001268250A patent/AU2001268250A1/en not_active Abandoned
- 2001-06-08 CA CA002411472A patent/CA2411472A1/en not_active Abandoned
- 2001-06-08 ES ES01946167T patent/ES2264697T3/es not_active Expired - Lifetime
- 2001-06-08 DE DE60119517T patent/DE60119517T2/de not_active Expired - Fee Related
- 2001-06-08 JP JP2002510534A patent/JP2004503237A/ja not_active Withdrawn
- 2001-06-08 WO PCT/US2001/018517 patent/WO2001096397A2/en not_active Ceased
- 2001-06-08 EP EP01946167A patent/EP1294874B1/de not_active Expired - Lifetime
- 2001-06-08 DK DK01946167T patent/DK1294874T3/da active
- 2001-06-08 NZ NZ523351A patent/NZ523351A/en unknown
- 2001-06-08 AT AT01946167T patent/ATE325874T1/de not_active IP Right Cessation
- 2001-06-08 PT PT01946167T patent/PT1294874E/pt unknown
-
2006
- 2006-07-26 CY CY20061101033T patent/CY1105153T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60119517D1 (de) | 2006-06-14 |
| DE60119517T2 (de) | 2007-03-08 |
| AU2001268250A1 (en) | 2001-12-24 |
| EP1294874B1 (de) | 2006-05-10 |
| NZ523351A (en) | 2004-10-29 |
| JP2004503237A (ja) | 2004-02-05 |
| ES2264697T3 (es) | 2007-01-16 |
| WO2001096397A3 (en) | 2002-05-02 |
| PT1294874E (pt) | 2006-09-29 |
| WO2001096397A2 (en) | 2001-12-20 |
| DK1294874T3 (da) | 2006-08-28 |
| CY1105153T1 (el) | 2010-03-03 |
| CA2411472A1 (en) | 2001-12-20 |
| EP1294874A2 (de) | 2003-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY155218A (en) | Small molecules useful in the treatment of inflammatory disease | |
| CY1116385T1 (el) | Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β | |
| EP2292771A3 (de) | Sense mRNA Therapie | |
| BR0012888A (pt) | Inibidores derivados de purina de proteìna tirosina sic quinase | |
| ATE362766T1 (de) | Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen | |
| EP1485381B8 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| AU2003218215A1 (en) | Azolylaminoazines as inhibitors of protein kinases | |
| AU2003220300A1 (en) | Compositions useful as inhibitors of protein kinases | |
| EP1569695A4 (de) | Antisense-modulationder apolipoprotein-b-expression | |
| NO20045677L (no) | Inhibitorer av JAK- og CDK2-proteinkinaser | |
| DE602004024374D1 (de) | Zusammensetzungen zur verwendung als protein-kinase-inhibitoren | |
| AU1922101A (en) | Human fgf-21 gene and gene expression products | |
| EA200300091A1 (ru) | Замещенные триазолопиримидины в качестве противораковых средств | |
| DE60027768D1 (de) | Behandlung von metastatischer krankheit | |
| DE60119517D1 (de) | Cd154 varianten und deren verwendung | |
| WO2003023004A3 (en) | Antisense modulation of fibroblast growth factor receptor 3 expression | |
| DE60137146D1 (de) | Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten | |
| EP1430072A4 (de) | Antisense-modulierung der expression des cholesterylestertransferproteins | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| ATE287886T1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer | |
| DE69736276D1 (de) | Menschliche dnase resistent gegen actininhibitoren | |
| DE69534633D1 (de) | Implantat und vektor zur behandlung von erworbenen krankheiten | |
| DE60239670D1 (de) | Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis | |
| EA200200518A1 (ru) | Способ и композиция для лечения заболеваний легких | |
| WO2003080800A3 (en) | Prevention and treatment of disease using angiogenesis-and/or tumor antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1294874 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |